- A record 31 scientific presentations and posters at the 2024 European Society for Human Genetics (ESHG) Annual Conference and 8 scientific presentations and posters at the 2024 American Cytogenomics Conference (ACC) will highlight the application of optical genome mapping (OGM) in genetic disorder, rare disease, and cancer research applications
- Bionano will host a sponsored session at ESHG featuring an overview of the Company's OGM workflow delivered by Bionano's chief medical officer, Dr. Alka Chaubey, a presentation from Dr. Laura Batlle Masó at Vall d'Hebron Institute of Research (Spain) on OGM's potential utility in resolving hereditary angioedema (HAE) cases, a presentation from Dr. Bart van der Sanden at Radboud UMC (Netherlands) on how OGM may be useful for the detection of structural variants (SVs) relevant to rare disease, and a presentation from Marlene Ek at Karolinska Institute (Sweden) highlighting OGM's ability to unveil more cytogenomic insights into multiple myeloma samples than traditional cytogenetic methods
- At ACC, a sponsored session will feature Dr. Mike Gallagher, market development manager at Bionano, highlighting OGM's ability to enhance detection of pathogenic variants and to advance genetic disease research. Dr. Gallagher will also introduce the latest innovations in the OGM workflow, including the Stratys™ system and VIA™ software
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the Company's robust participation at two upcoming cytogenetics conferences, the 2024 European Society for Human Genetics (ESHG) Annual Conference and the 2024 American Cytogenomics Conference (ACC), with a record 39 scientific presentations and posters across the two conferences that highlight the utility of the Company's OGM workflow for applications in genetic disease, cancer, and rare disease research and discussing the latest advances to the Company's suite of products, including the high throughput Stratys system and VIA software.
ESHG brings together industry and academic professionals annually to discuss new technologies and advances in the field of human genetics. ESHG sessions will take place June 1-4, 2024 virtually and in Berlin, Germany.
ACC is a biennial conference focused on new technologies and advances in the field of cytogenetics. ACC will be held June 2-5, 2024 in Norfolk, Virginia.
Bionano will host a sponsored session at ESHG featuring an overview of the Company's OGM workflow delivered by Bionano's chief medical officer, Dr. Alka Chaubey, a presentation from Dr. Laura Batlle Masó at Vall d'Hebron Institute of Research (Spain) on OGM's potential utility in resolving hereditary angioedema (HAE) cases, a presentation from Dr. Bart van der Sanden at Radboud UMC (Netherlands) covering how OGM may be useful for the detection of SVs relevant to rare disease, and a presentation from Marlene Ek at Karolinska Institute (Sweden) highlighting OGM's ability to unveil more cytogenomic insights into multiple myeloma samples than traditional cytogenetic methods.
At ACC, a sponsored session will feature Dr. Mike Gallagher, market development manager at Bionano, highlighting OGM's ability to enhance detection of pathogenic variants and to advance genetic disease research. Dr. Gallagher will also introduce the latest innovations in the OGM workflow, including the Stratys system and VIA software.
Erik Holmlin, PhD, president and chief executive officer of Bionano, stated, "We are excited to see the progress that the global OGM community is making, which is highlighted by the growth in the number of scientific posters and presentations on OGM from the last time the ESHG and ACC conferences were held. We believe this expansion demonstrates the increased customer adoption of OGM, with routine and repeated utilization for innovative research into genetic disorders, cancer and rare disease."
ESHG scientific presentations and poster sessions:
Scientific presentations and poster sessions on OGM at ESHG take place in the exhibition halls unless otherwise noted.
Abstract/ Poster Number | Title | Authors | Presented |
P14.015.A | Deciphering a complex short size RERE rearrangement: importance of combined approaches for duplication interpretation | Fauqueux J. | June 2, 2024 10:15-11:15 AM CEST |
P01.065.A | A Canadian lab's experience using optical genome mapping to clinically genotype hematological neoplasms | Hamadeh Z. | June 2, 2024 10:15-11:15 AM CEST |
P03.025.A | Characterization of a complex rearrangement between three chromosomes in a fetus with skeletal anomalies by optical genome mapping | Heinrich U. | June 2, 2024 10:15-11:15 AM CEST |
P16.077.A | Accurate identification of pathogenic structural variants guided by multi-platform comparison | Moeinzadeh M. | June 2, 2024 10:15-11:15 CEST |
P01.163.B | Deciphering the molecular complexity of the IKZF1 plus profile using optical genome mapping | Lühmann J. | June 2, 2024 16:45-17:45 PM CEST |
P12.023.B | SORD and SORD2P inversion: long read sequencing identifies a novel genetic mechanism underlying inherited neuropathy | Manini A. | June 2, 2024 16:45-17:45 PM CEST |
P04.029.B | Optical genome mapping facilitates rapid characterization of structural variants in families with developmental eye anomalies | Merepa S. | June 2, 2024 16:45-17:45 PM CEST |
P01.007.C | Large genomic rearrangement: tandem duplication and triplication in BRCA1 gene causative for hereditary breast and ovarian cancer | Aldrige Allister B. | June 3, 2024 10:15-11:15 AM CEST |
P15.102.C | Establishing ultra-rapid genome sequencing in neonatal and pediatric intensive care units in Germany – project Baby Lion | Auber B. | June 3, 2024 10:15-11:15 AM CEST |
P14.029.C | Optical genome mapping of a patient with ring chromosome 3 shows the importance of choosing the proper reference genome for the analysis | Burssed B. | June 3, 2024 10:15-11:15 AM CEST |
P14.025.C |